Refanezumab

Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke.^[1][2]

Refanezumab

Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	myelin-associated glycoprotein
Clinical data
Other names	GSK249320
ATC code	none
Identifiers
CAS Number	1233953-61-1
ChemSpider	none
UNII	3ZZ278643V
Chemical and physical data
Formula	C6608H10156N1732O2064S44
Molar mass	148298.64 g·mol−1

This drug was developed by GlaxoSmithKline.